The topoisomerases are a family of nuclear enzymes that solve a fundamental topological problem created by the double-helical structure of DNA (deoxyribonucleic acid): as the replication fork advances or RNA (ribonucleic acid) polymerase transcribes, the DNA ahead of these complexes becomes overwound (positively supercoiled), and torsional stress accumulates that would stall both processes if not relieved. Topoisomerases relieve this supercoiling by transiently cleaving and rejoining DNA strands. The topoisomerase inhibitors exploit this catalytic mechanism by trapping the enzyme in a covalent intermediate with DNA, converting a necessary cellular enzyme into a lethal DNA-damaging agent.1
Topoisomerase I (Topo I) relieves DNA supercoiling by making a transient single-strand break (nick) in dsDNA. The enzyme forms a covalent 3-prime-phosphotyrosine bond between an active-site tyrosine residue and the cleaved strand, creating a swivel point around which the intact complementary strand can rotate to relieve torsional stress. After rotation reduces superhelical tension, Topo I religates the cleaved strand by reversing the transesterification reaction, and the enzyme dissociates from intact, relaxed dsDNA. The intermediate in which the enzyme is covalently bound to DNA is called the cleavable complex (or covalent complex). Under normal enzymatic conditions, this cleavable complex is transient, lasting fractions of a millisecond. Camptothecin-class drugs bind at the interface between the Topo I protein and the dsDNA at the cleavable complex, inserting between the flanking DNA base pairs and stabilizing the complex in a geometry that prevents religation. The stabilized cleavable complex is not inherently lethal; it becomes lethal when a replication fork or transcription complex collides with it, converting the reversible nick into an irreversible double-strand break (DSB) that triggers the DNA damage response and apoptosis. This collision-dependent lethality explains why camptothecins are S-phase-specific and why dividing cells are preferentially killed.12
Topoisomerase II (Topo II) resolves both positive and negative supercoiling and decatenates (separates) sister chromatid pairs after replication by making transient DSBs in dsDNA. The enzyme functions as a homodimer, with each protomer contributing an active-site tyrosine that forms a 5-prime-phosphotyrosine bond with the cleaved strand, generating a four-base-pair staggered DSB. A second intact DNA duplex is then passed through the DSB (the strand-passage mechanism) before religation. Two isoforms are clinically relevant: Topo II-alpha (encoded by TOP2A), which is cell cycle regulated and expressed predominantly in dividing cells, and Topo II-beta (encoded by TOP2B), which is expressed in postmitotic cells including cardiomyocytes and neurons. Epipodophyllotoxins (etoposide, teniposide) and anthracyclines (doxorubicin, epirubicin, daunorubicin) stabilize the Topo II cleavable complex by intercalating into the DSB at the point of enzyme-DNA covalency, preventing religation and generating persistent DSBs. The preferential toxicity of these agents to Topo II-alpha-expressing cells provides their selective antitumor activity, while the activity of some agents at Topo II-beta in cardiomyocytes contributes to cardiotoxicity.2
Topo I inhibitors (camptothecins) produce single-strand breaks stabilized into lethal DSBs only at replication forks: they are S-phase-specific and do not cause the secondary leukemias or severe cumulative cardiotoxicity associated with Topo II inhibitors. Topo II inhibitors (anthracyclines, epipodophyllotoxins) produce DSBs in any phase of the cell cycle and carry risks of treatment-related acute myeloid leukemia (AML) and, for anthracyclines, cumulative cardiomyopathy. Etoposide-related secondary AML (typically with MLL gene rearrangements at chromosome 11q23) has a latency of 1 to 3 years, shorter than alkylating agent-related AML (5 to 7 years). This difference in safety profile influences the choice between camptothecin-based and anthracycline-based regimens in young patients receiving curative-intent therapy.
Irinotecan and topotecan are semisynthetic derivatives of the plant alkaloid camptothecin, both acting as Topo I inhibitors through the cleavable complex mechanism. Their clinical profiles differ substantially: irinotecan is used primarily in colorectal and gastrointestinal cancers and has a complex prodrug pharmacology governed by a clinically significant pharmacogenomic variant, while topotecan is used in small cell lung cancer (SCLC) and ovarian cancer and has a more straightforward pharmacokinetic profile.3
Irinotecan is an inactive prodrug that requires hydrolysis of its bulky dipiperidino side chain by carboxylesterase enzymes (CES1 and CES2) in the liver, intestinal wall, and tumor tissue to generate the active Topo I-inhibiting metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). SN-38 is approximately 100 to 1,000 times more potent than the parent drug as a Topo I inhibitor. The primary inactivation pathway for SN-38 is glucuronidation by UGT1A1 (UDP [uridine diphosphate]-glucuronosyltransferase isoform 1A1) in the liver, converting SN-38 to the inactive SN-38G (SN-38 glucuronide). SN-38G is excreted in bile; however, in the intestinal lumen, bacterial beta-glucuronidases deconjugate SN-38G back to active SN-38, which is reabsorbed (enterohepatic recirculation) or causes direct mucosal toxicity. This enterohepatic cycle of SN-38 generation in the gut is a key driver of irinotecan-induced late diarrhea (onset more than 24 hours after infusion), one of the two major dose-limiting toxicities of the drug.34
The two distinct diarrhea syndromes associated with irinotecan require mechanistically different treatments and must not be confused. Early diarrhea, occurring within 24 hours of irinotecan infusion (often during or immediately after the infusion), is cholinergic in mechanism: irinotecan and its metabolites inhibit acetylcholinesterase (AChE [acetylcholinesterase]), causing a cholinergic excess syndrome that includes abdominal cramping, diaphoresis, flushing, lacrimation, rhinorrhea, and early-onset diarrhea. Treatment is atropine 0.25 to 1 mg given intravenously or subcutaneously. Atropine prophylaxis can also be given before irinotecan infusion in patients who have experienced cholinergic symptoms in prior cycles. Late diarrhea (onset more than 24 hours after infusion) is caused by direct mucosal toxicity from intraluminal SN-38, the active Topo I-inhibiting metabolite generated by bacterial beta-glucuronidase activity in the gut. Treatment is high-dose loperamide: 4 mg at the first loose stool, then 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours. Patients must be instructed in this protocol before each irinotecan cycle. Loperamide is not effective for early cholinergic diarrhea and atropine is not effective for late diarrhea; confusing the two syndromes leads to treatment failure.3
The pharmacogenomic variant most relevant to irinotecan dosing is UGT1A1*28, a promoter polymorphism consisting of an extra TA dinucleotide repeat in the TATA (Transcription factor IID-binding) box of the UGT1A1 promoter (7 repeats [TA]₇ vs the wild-type 6 repeats [TA]₆). The additional repeat reduces UGT1A1 promoter activity, resulting in approximately 30 to 70% lower UGT1A1 enzyme expression and correspondingly reduced glucuronidation capacity for SN-38. Patients homozygous for UGT1A1*28 (the UGT1A1*28/*28 genotype, present in approximately 10% of North Americans of European ancestry) are at substantially increased risk of severe neutropenia and grade 3 to 4 diarrhea at standard irinotecan doses because SN-38 accumulates to higher plasma concentrations and for longer durations due to impaired glucuronidation. The FDA label for irinotecan recommends considering a dose reduction for UGT1A1*28/*28 patients. In practice, UGT1A1 genotyping is increasingly performed before high-dose irinotecan regimens (such as FOLFIRI or FOLFIRINOX) to guide starting dose selection. Heterozygous patients (UGT1A1*1/*28, approximately 40% of North Americans) have intermediate risk and usually tolerate standard doses with close monitoring.4
Topotecan does not require prodrug activation and is active as the parent compound. It is a substrate for the breast cancer resistance protein (BCRP [breast cancer resistance protein], encoded by ABCG2 [ATP (adenosine triphosphate)-binding cassette subfamily G member 2]), which acts as an efflux transporter limiting oral absorption and mediating cellular efflux resistance. Topotecan is primarily renally excreted, and dose reduction is required when creatinine clearance falls below 40 mL/min. The dose-limiting toxicity is myelosuppression, predominantly neutropenia. Topotecan is used in relapsed SCLC (where it is one of few active agents in the second-line setting), recurrent ovarian cancer, and relapsed cervical cancer. The oral formulation of topotecan achieves approximately 30 to 40% bioavailability and is limited by BCRP-mediated efflux in the gastrointestinal mucosa.3
Every patient starting irinotecan must receive written instructions distinguishing early from late diarrhea and specifying the correct treatment for each. Early cholinergic diarrhea (within 24 hours) is treated with atropine; late diarrhea (after 24 hours) is treated with high-dose loperamide starting at the first loose stool. Patients who confuse the two and take loperamide for early cholinergic diarrhea will get no relief; patients who take nothing for late diarrhea can become severely dehydrated and neutropenic. Verbal counseling in clinic is insufficient given the severity of consequences of a missed late diarrhea episode; written action plans are mandatory. Hospitalization is required for any patient who develops grade 3 or 4 late diarrhea with concurrent neutropenia, as this combination is potentially fatal without prompt IV hydration and antibiotics.
Etoposide and teniposide are semisynthetic derivatives of podophyllotoxin, a plant alkaloid from the May apple, that act as Topo II (topoisomerase II) poisons by stabilizing the Topo II-DNA (topoisomerase II-DNA) cleavable complex and preventing religation of double-strand breaks. They are chemically distinct from the vinca alkaloids and taxanes despite sharing the same botanical origin class name of podophyllum derivatives, and their mechanism is entirely different from podophyllotoxin itself, which acts on tubulin rather than Topo II.5
Etoposide is the most widely used epipodophyllotoxin in current oncology practice. It is incorporated into multiple curative-intent regimens including BEP (bleomycin, etoposide, cisplatin) for testicular germ cell tumors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for high-risk Hodgkin lymphoma, and EP (etoposide, cisplatin) for SCLC (small cell lung cancer). Etoposide stabilizes the Topo II-alpha-DNA cleavable complex specifically during the G2 (gap 2) phase of the cell cycle and at the G2/M (gap 2/mitosis) boundary, when Topo II-alpha activity is highest. The mechanism results in persistent DSBs (double-strand breaks) that activate ATM (ataxia-telangiectasia mutated kinase) and the DNA (deoxyribonucleic acid) damage response, ultimately triggering p53-dependent and p53-independent apoptosis. Schedule dependency is a clinically relevant pharmacological feature of etoposide: prolonged oral dosing over 5 to 21 days achieves more sustained plasma concentrations below the threshold for acute cytotoxicity while maintaining cytostatic Topo II inhibition, and produces higher response rates in SCLC than equivalent-dose intravenous bolus administration. This observation led to the widespread use of oral etoposide in elderly or frail SCLC patients who cannot tolerate intravenous cisplatin-based combinations.5
Etoposide is eliminated by a combination of renal excretion of unchanged drug (approximately 30 to 50% of administered dose) and hepatic metabolism by CYP3A4 (cytochrome P450 3A4) to the catechol metabolite, which can undergo further oxidation to the etoposide ortho-quinone, a reactive electrophile implicated in the mutagenic properties of etoposide. Dose reduction is required in patients with impaired renal function (creatinine clearance below 50 mL/min reduces etoposide clearance by approximately 30%) and in hepatic dysfunction. Bioavailability of oral etoposide is approximately 50% with high inter-patient variability (20 to 80%); concurrent food reduces absorption modestly. The dose-limiting toxicity is myelosuppression, with neutropenia as the predominant finding and a nadir at 7 to 14 days. Mucositis occurs particularly with high-dose regimens. The most serious long-term toxicity is treatment-related secondary AML (acute myeloid leukemia): etoposide-related secondary leukemia is characterized by translocations involving the MLL (mixed lineage leukemia) gene at chromosome 11q23 or, less commonly, the AML1 (acute myeloid leukemia 1) gene at chromosome 21q22, has a median latency of 1 to 3 years from etoposide exposure, and does not follow the prior myelodysplastic syndrome phase typically seen with alkylating agent-related AML.5
Teniposide shares the same Topo II-alpha mechanism as etoposide but is more lipophilic, more extensively protein-bound (99% vs 95% for etoposide), and exhibits slower plasma clearance. It is used primarily in refractory ALL (acute lymphoblastic leukemia) in pediatric patients and is less widely used than etoposide in adult oncology. Because of its high protein binding, renal dose adjustment is less critical than for etoposide, but displacement by other highly protein-bound drugs can increase free teniposide concentrations and potentiate toxicity. Both etoposide and teniposide are vesicant drugs; extravasation causes local tissue injury requiring prompt management with saline infiltration and cold compresses.5
The cumulative lifetime risk of treatment-related AML from etoposide exposure is approximately 1 to 2% in testicular cancer survivors treated with BEP and approximately 3 to 5% in Hodgkin lymphoma patients treated with BEACOPP. These risks are meaningfully different from zero and must be disclosed during informed consent for curative-intent regimens containing etoposide. The distinguishing features of etoposide-related secondary AML (MLL-rearrangement, latency 1 to 3 years, de novo AML presentation without prior MDS phase) are worth knowing because the morphology and treatment of MLL-rearranged AML differ from standard AML. In patients who survive the primary cancer and develop AML at 1 to 3 years after etoposide-containing therapy, MLL cytogenetics should be specifically requested as part of the AML workup.
The anthracyclines are among the most effective antitumor agents in clinical oncology, with activity across breast cancer, sarcoma, lymphoma, leukemia, and gastric cancer. Their clinical use is inextricably linked to the risk of dose-dependent cumulative cardiomyopathy, which imposes absolute lifetime dose limits and requires active cardiotoxicity surveillance strategies.7
Doxorubicin (Adriamycin) exerts antitumor activity through at least three simultaneous mechanisms, which distinguishes it from the single-mechanism Topo II inhibitors. First, and most clearly established, doxorubicin intercalates into dsDNA by inserting its planar anthracycline chromophore between adjacent base pairs, distorting the DNA (deoxyribonucleic acid) helix and stabilizing the Topo II-alpha cleavable complex, generating persistent DSBs. Second, doxorubicin undergoes one-electron reduction by cytoplasmic and mitochondrial reductases (NADH [nicotinamide adenine dinucleotide, reduced form] dehydrogenase, NADPH [nicotinamide adenine dinucleotide phosphate, reduced form] cytochrome P450 reductase, and mitochondrial complex I) to a semiquinone radical intermediate that donates its extra electron to molecular oxygen, generating superoxide anion (O₂˙⁻) and subsequently hydrogen peroxide (H₂O₂) and hydroxyl radical (HO˙) through Fenton chemistry. These reactive oxygen species (ROS) damage DNA, proteins, and lipid membranes in a manner that is not fully reversed by leucovorin or any other metabolic countermeasure. Third, doxorubicin binds to and intercalates into the mitochondrial inner membrane lipid cardiolipin, disrupting electron transport chain function and triggering mitochondrial apoptosis pathways. The cardiomyopathy mechanism involves the combination of ROS generation (cardiomyocytes are particularly vulnerable because they express relatively low levels of antioxidant enzymes catalase and superoxide dismutase compared to hepatocytes), cardiolipin binding, and Topo II-beta-mediated DSBs in postmitotic cardiomyocyte nuclei.678
The pharmacokinetics of doxorubicin are characterized by extensive tissue distribution (volume of distribution approximately 700 to 1,100 L/m²), a triphasic plasma decay with a terminal half-life of 20 to 48 hours, extensive hepatic metabolism by carbonyl reductase to the active metabolite doxorubicinol, and biliary excretion. Hepatic dose modification is required: for bilirubin 1.2 to 3.0 mg/dL, give 50% of the dose; for bilirubin above 3.0 mg/dL, give 25% of the dose. Renal excretion accounts for only approximately 5 to 12% of doxorubicin elimination; renal dose adjustment is generally not required. The dose-limiting acute toxicity is myelosuppression with nadir at 10 to 14 days. Significant cumulative dose-dependent cardiotoxicity is observed above lifetime cumulative doses of 450 to 550 mg/m² for conventional doxorubicin; the incidence of clinical heart failure rises steeply with each additional 100 mg/m² above this threshold. This absolute dose ceiling defines the limit of repeated anthracycline-containing chemotherapy cycles a patient can receive over a lifetime and must be tracked cumulatively across all prior anthracycline exposures.8
Epirubicin is the 4-prime-epimer of doxorubicin, differing only in the stereochemical configuration of the hydroxyl group on the sugar moiety. This structural change results in faster glucuronidation and biliary clearance, a shorter plasma half-life, and approximately 20% lower cardiotoxicity per unit dose compared to doxorubicin, allowing a higher per-cycle dose. The cumulative dose limit for epirubicin before significant cardiac risk is approximately 900 mg/m². Epirubicin is used in breast cancer (FEC [fluorouracil, epirubicin, cyclophosphamide]) and gastric cancer (ECF [epirubicin, cisplatin, fluorouracil]). Despite its lower per-dose cardiotoxicity, the same lifetime cumulative dose monitoring and cardiac surveillance requirements apply. Daunorubicin and idarubicin are anthracyclines used in AML (acute myeloid leukemia) induction therapy; idarubicin lacks the 4-prime-methoxy group of doxorubicin, making it more lipophilic with greater CNS (central nervous system) penetration, and is preferred by many centers for AML induction because it achieves higher intranuclear concentrations.7
Liposomal doxorubicin (pegylated liposomal doxorubicin, PLD) encapsulates doxorubicin in polyethylene glycol (PEG)-coated liposomes that circulate with a very long plasma half-life (approximately 45 to 90 hours) and exploit the enhanced permeability and retention (EPR) effect: the disordered, leaky vasculature of tumors allows preferential extravasation of nano-scale liposomal particles, whereas normal well-organized capillaries do not. PEG coating (PEGylation) reduces recognition by the mononuclear phagocyte system, extending circulation time and allowing tumor accumulation. PLD produces a dramatically different toxicity profile from conventional doxorubicin: cardiotoxicity is substantially reduced (cumulative dose limit of 550 mg/m² applied to PLD is generally considered safe at doses well above the conventional doxorubicin limit), myelosuppression is reduced, and alopecia is significantly less. The new dose-limiting toxicities of PLD are palmar-plantar erythrodysesthesia (hand-foot syndrome, identical to the capecitabine toxicity), occurring in up to 40 to 50% of patients, and mucositis, both of which are managed by dose reduction and cycle delay rather than by specific antidotes. PLD is approved for ovarian cancer, AIDS (acquired immunodeficiency syndrome)-related Kaposi sarcoma, and multiple myeloma.8
The cardiotoxicity risk of anthracyclines is cumulative and irreversible; there is no anthracycline antidote that restores lost cardiomyocytes. Every physician prescribing anthracycline-containing chemotherapy must know the patient's lifetime cumulative anthracycline dose expressed in doxorubicin-equivalents. The conversion factors are approximate but clinically necessary: 1 mg doxorubicin = 1 mg liposomal doxorubicin = 0.5 mg epirubicin = 0.5 mg daunorubicin = 0.25 mg idarubicin. A patient who received 240 mg/m² of doxorubicin for breast cancer a decade ago and now requires retreatment for relapsed lymphoma has already consumed approximately 44% of their safe lifetime doxorubicin equivalent dose. Concurrent cardiotoxic exposures (trastuzumab, radiation to the mediastinum, hypertension, diabetes) lower the effective cumulative dose threshold for clinical cardiomyopathy and mandate earlier cardiologic consultation and consideration of cardiac surveillance imaging.
Bleomycin and actinomycin D are antitumor antibiotics with distinct mechanisms of DNA (deoxyribonucleic acid) damage and toxicity profiles that differ markedly from the topoisomerase inhibitors. Both are used in curative-intent regimens for specific cancer types, and both carry severe organ-specific toxicities that require active management and monitoring.9
Bleomycin is a glycopeptide antibiotic derived from Streptomyces verticillus that kills cells by generating reactive oxygen species (ROS) that directly cleave DNA strands. The mechanism involves bleomycin binding to Fe(II) (ferrous iron) through its metal-binding domain to form a bleomycin-Fe(II) complex, which enters cells and chelates iron in the nucleus. In the presence of molecular oxygen, the bleomycin-Fe(II) complex is oxidized to a bleomycin-Fe(III) intermediate that reduces molecular oxygen to superoxide and then to the hydroxyl radical (HO˙) through an activated oxygen intermediate called the activated bleomycin complex or bleomycin peroxide. This activated complex cleaves DNA strands preferentially at 5-prime-GC-3-prime and 5-prime-GT-3-prime sequences, producing predominantly single-strand breaks but also DSBs in a ratio of approximately 10:1. Bleomycin is cell cycle specific, with maximal cytotoxicity in G2 (gap 2) phase and M phase (mitosis), consistent with the observation that cell lines arrested in G2 are exquisitely bleomycin-sensitive. Bleomycin hydrolase, a cytoplasmic aminopeptidase, inactivates bleomycin by hydrolysis of the terminal amino group; high bleomycin hydrolase activity in squamous epithelial cells and hepatocytes confers relative resistance, while low activity in lung and skin explains the organ-specific toxicities of the drug.9
The dose-limiting and potentially fatal toxicity of bleomycin is pulmonary toxicity, which manifests as bleomycin-induced pneumonitis (BIP) progressing in severe cases to pulmonary fibrosis. Pulmonary toxicity occurs in approximately 10% of patients receiving standard BEP (bleomycin, etoposide, cisplatin) doses and in up to 40% of patients at very high cumulative doses; it is associated with cumulative lifetime bleomycin doses above 400 units, age above 40 years, prior or concurrent thoracic radiation, renal impairment (bleomycin is renally eliminated), and high inspired oxygen concentration during anesthesia. The clinical presentation begins with a non-productive cough, dyspnea on exertion, and bilateral basal crepitations on auscultation; high-resolution chest CT (computed tomography) shows ground-glass opacities and reticular changes in the lower lung zones. Diffusing capacity for carbon monoxide (DLCO) falls before overt symptoms develop, and serial DLCO measurements are used for monitoring in patients receiving BEP. The radiological and clinical features of BIP overlap substantially with pneumonia and pulmonary metastases, making diagnosis challenging. Treatment is bleomycin discontinuation; corticosteroids are used in moderate to severe cases but evidence of benefit is limited.9
The most feared complication of bleomycin therapy is post-operative adult respiratory distress syndrome (ARDS) triggered by high inspired oxygen fractions during general anesthesia, which can be fatal. Anesthesiologists must be informed of prior bleomycin exposure for any patient requiring surgery; inspired oxygen fraction (FiO₂) must be kept as low as safely tolerable during and after anesthesia. The proposed mechanism is that bleomycin-sensitized lung tissue generates excess ROS (reactive oxygen species) when exposed to high oxygen tension, overwhelming pulmonary antioxidant defenses. There is no established safe interval after bleomycin beyond which normal anesthetic FiO₂ can be used without risk.910
In the BEP regimen for testicular germ cell tumors, bleomycin is administered at 30 units weekly for 12 weeks. Because young men with testicular cancer have curative-intent treatment with high anticipated long-term survival, the decision about whether to include bleomycin in the regimen versus substituting etoposide alone (EP regimen) requires careful consideration of individual pulmonary risk. The IGCCCG (International Germ Cell Cancer Collaborative Group) good-risk category patients (which includes the majority of testicular GCT patients) achieve equivalent cure rates with either 3 cycles of BEP or 4 cycles of EP, though ongoing trials continue to refine this. Patients with pre-existing pulmonary disease, reduced DLCO, or significant bleomycin risk factors may be preferentially managed with EP (four cycles) rather than BEP to avoid bleomycin-related pulmonary morbidity.10
Actinomycin D (dactinomycin) is an actinomycete-derived antibiotic that intercalates into dsDNA by inserting its flat phenoxazinone chromophore between GC (guanine-cytosine) base pairs and stabilizing this intercalation through non-covalent interactions between its two cyclic pentapeptide side chains and the minor groove. This intercalation physically blocks the movement of RNA (ribonucleic acid) polymerase along the DNA template, inhibiting transcription of virtually all RNA species (mRNA [messenger RNA], rRNA [ribosomal RNA], and tRNA [transfer RNA]) without direct inhibition of DNA replication at clinical concentrations. At higher concentrations, actinomycin D also inhibits Topo II. Actinomycin D is a potent radiation sensitizer because it inhibits the transcription of DNA repair enzymes required after radiation-induced DNA damage. It is used in Wilms tumor (nephroblastoma) in children (where it is a standard component of regimens achieving cure rates exceeding 90% in localized disease), gestational trophoblastic disease (where it produces high complete response rates in low-risk methotrexate-resistant disease), Ewing sarcoma, and rhabdomyosarcoma. The dose-limiting toxicities are myelosuppression and mucositis; actinomycin D is also an extreme vesicant requiring scrupulous administration technique to prevent extravasation injury.9
The combination of prior bleomycin exposure and high inspired oxygen concentration during general anesthesia can trigger acute ARDS in the perioperative period, with reported mortality rates exceeding 50% in severe cases. The proposed mechanism involves bleomycin-sensitized lung tissue generating excess ROS when exposed to high oxygen tension, overwhelming pulmonary antioxidant defenses. The key management principle is that FiO₂ should be kept at the lowest level consistent with adequate oxygen saturation (target SpO₂ 93 to 95%) during and after anesthesia in any patient with a history of bleomycin therapy. This requirement does not expire with time; there is no established safe interval after bleomycin beyond which normal FiO₂ can be used. Inform the anesthesia team of bleomycin history before any elective or emergency procedure requiring general anesthesia, and document this history prominently in the patient's chart.
Anthracycline-induced cardiomyopathy is the most clinically significant toxicity of this drug class, representing an irreversible, cumulative injury to cardiomyocytes that limits the total lifetime dose that can be safely administered and produces a dilated cardiomyopathy with identical histopathological and echocardiographic features to idiopathic dilated cardiomyopathy. Understanding its mechanism is essential for appropriate cumulative dose monitoring, cardiac surveillance, and the rational use of cardioprotective strategies.11
Two molecular mechanisms have been identified as major contributors to anthracycline cardiomyopathy, and they are mechanistically distinct. The first, and historically most emphasized, is oxidative stress from anthracycline-iron complex formation and ROS (reactive oxygen species) generation. In cardiomyocytes, doxorubicin is reduced to its semiquinone radical, which donates electrons to molecular oxygen generating superoxide. Cardiomyocytes are uniquely vulnerable to this oxidative stress because they have high mitochondrial density (to support continuous contractile function), express relatively low levels of catalase and GSH-Px (glutathione peroxidase) compared to hepatocytes, and are postmitotic (unable to replace damaged cells by division). The result is progressive mitochondrial dysfunction, myofilament degradation, and cardiomyocyte apoptosis that accumulates silently over months to years before left ventricular systolic dysfunction becomes clinically apparent. The second mechanism, identified more recently, involves Topo II-beta-mediated DSBs in cardiomyocyte nuclei. Doxorubicin stabilizes the Topo II-beta cleavable complex in postmitotic cardiomyocytes, generating persistent DSBs that activate p53-dependent transcriptional reprogramming and apoptosis pathways in cardiomyocytes, and simultaneously suppress expression of genes encoding mitochondrial biogenesis and electron transport chain components.211
The cumulative dose relationship for anthracycline cardiotoxicity is non-linear. The incidence of clinical congestive heart failure (CHF) attributable to doxorubicin is approximately 3 to 5% at 400 mg/m², 7 to 26% at 550 mg/m², and 18 to 48% at 700 mg/m², as established in large retrospective series. These ranges reflect the substantial variation contributed by concurrent cardiotoxic risk factors. The established risk factors for anthracycline cardiomyopathy beyond cumulative dose include age extremes (pediatric patients and patients above 65 years), female sex (approximately 1.5-fold higher risk than male patients at equivalent doses), pre-existing hypertension (HTN), diabetes mellitus (DM), and coronary artery disease (CAD), prior mediastinal radiation (which independently damages cardiomyocytes and reduces the safe anthracycline threshold), concurrent use of trastuzumab (which combines additively with anthracyclines in cardiac toxicity risk, which is why sequential rather than concurrent trastuzumab-anthracycline administration is mandated), and the administration schedule (bolus infusion produces higher peak plasma levels and greater cardiotoxicity than 48- to 96-hour continuous infusion at equivalent total dose).11
Dexrazoxane is the only FDA-approved cardioprotective agent for anthracycline-induced cardiomyopathy. It is a cyclic derivative of EDTA (ethylenediaminetetraacetic acid) that enters cells where it is hydrolyzed by dihydroorotase to an open-ring form (ADR-925) that chelates intracellular free iron, preventing the formation of doxorubicin-iron complexes required for ROS generation. Dexrazoxane also acts as a Topo II inhibitor in its own right (as a Topo II catalytic inhibitor, not a Topo II poison), which may contribute to its cardioprotection by displacing doxorubicin from the Topo II-beta complex in cardiomyocytes. Dexrazoxane is given intravenously 30 minutes before each doxorubicin dose at a dexrazoxane-to-doxorubicin ratio of 10:1 (mg/mg). Its approved indication is breast cancer patients with metastatic disease who have received more than 300 mg/m² of doxorubicin and who may benefit from continued anthracycline therapy. Early concerns that dexrazoxane might reduce antitumor efficacy of doxorubicin have not been substantiated in randomized trials; no significant reduction in response rate or survival has been demonstrated. However, dexrazoxane itself has mild myelosuppressive effects and may increase the risk of second primary malignancies in pediatric patients receiving it with anthracycline-based chemotherapy, a finding that has limited its use in pediatric oncology.12
Baseline echocardiography or MUGA (multigated acquisition scan) with left ventricular ejection fraction (LVEF) assessment is required before initiating anthracycline therapy. Repeat cardiac imaging is recommended at cumulative doses of 250 to 300 mg/m² doxorubicin equivalent, at the end of planned therapy, and annually thereafter in high-risk patients. A decline in LVEF of 10 or more percentage points to below 53%, or any LVEF below 50% during therapy, requires cardiology consultation and should prompt consideration of dose reduction or treatment discontinuation. Troponin monitoring (cardiac troponin I or T) is increasingly used as an early marker of subclinical cardiomyocyte injury; troponin elevation after a doxorubicin cycle predicts long-term LVEF decline. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and beta-blockers initiated at the first sign of subclinical cardiac dysfunction may prevent progression to overt heart failure; cardio-oncology consultation is appropriate for any patient with documented anthracycline-related cardiac dysfunction.
Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.
doi:10.1038/nrc1977Pommier Y, Sun Y, Huang SN, Nitiss JL. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol. 2016;17(11):703–721.
doi:10.1038/nrm.2016.111Pizzolato JF, Saltz LB. The camptothecins. Lancet. 2003;361(9376):2235–2242.
doi:10.1016/S0140-6736(03)13780-4Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2(1):43–47.
doi:10.1038/sj.tpj.6500072Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514–1521.
doi:10.1016/S0959-8049(98)00228-7Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
doi:10.1124/pr.56.2.6Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19(6):670–686.
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.
doi:10.1002/cncr.11407Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer. 2005;5(2):102–112.
doi:10.1038/nrc1547de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19(6):1629–1640.
doi:10.1200/JCO.2001.19.6.1629Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332(26):1738–1743.
doi:10.1056/NEJM199506293322602Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer: a randomized trial. J Clin Oncol. 1997;15(4):1318–1332.
doi:10.1200/JCO.1997.15.4.1318